AI Drug Discovery Spurs Biotech ETF Strength

For investors, the implication is that AI is no longer just a chip and cloud-computing story; it is becoming a healthcare platform play with potential spillovers across drug makers, diagnostics firms and semiconductor suppliers. The setup also helps explain why the biotech ETF IBB and the broader biotech gauge NBI have both stayed elevated, with IBB closing at 207.33 on Sept. 8, above its 200-day moving average of 177.66, while NBI finished at 7,236.34 on Sept. 4, far above its 200-day average of 6,080.55.

The rally has come alongside signs that investors are still willing to pay for AI-linked healthcare upside even as the sector remains technically extended. IBB’s relative strength index was 54.1 on Sept. 8 after reaching 83.3 in August, while NBI’s RSI stood at 61.5 on Sept. 4 after a similar overbought spike earlier in the month.

Haas also warned that chip shortages remain a bottleneck for AI’s expansion, a reminder that the medical promise depends on the same hardware supply chain driving the rest of the AI boom. Arm, which designs processors used across hundreds of billions of devices, sits at the center of that trade, while Nvidia remains the market’s most aggressively bid AI name, with Adalytica’s Nvidia earnings sentiment reading 96 out of 100, or “Extreme Greed.”

The bigger narrative is that AI is broadening from productivity software and data centers into biology, where better models and better training data could eventually improve screening, speed up treatment development and deepen demand for compute. The near-term catalyst is whether more oncology companies can turn that thesis into measurable trial gains, with investors watching for clinical updates, AI drug-discovery partnerships and any easing of the chip constraints Haas says are still slowing the industry.